Infusystem Holdings Stock Earnings Reports

InfuSystem reported Q1 FY2026 revenue of $33.7M (GAAP down ~$1M YoY, but +1.7% pro forma after adjusting for a $7.1M annualized reduction from the GE Healthcare biomedical services contract restructuring). Adjusted EBITDA was approximately $6.3–6.4M, roughly in line with last year, lifting adjusted EBITDA margin to 18.9% from 18.2%. Key operational themes: (1) ERP go-live on March 1, 2026 — successful initial implementation with typical early stabilization work, expected benefits include improved productivity, pricing visibility, device utilization and working capital optimization; ERP-related costs were higher in the quarter but are expected to taper starting Q2 and deliver benefits over time. (2) Wound care is a fast-growing strategic product category (Q1 wound care revenue $2.1M, +~112% YoY), driven largely by new compression device suppliers (PCDs and adjustable compression wraps) and favorable reimbursement dynamics. Device Solutions revenue fell (down 17%) largely due to the GE contract restructuring and a prior-year customer rental buyout; Patient Services revenue grew ~6.4% led by oncology and wound care. Gross margin improved to ~58% as lower-cost field service work partially offset revenue declines. SG&A decreased slightly vs prior year but included higher IT/ERP spend and increased wages and healthcare costs. Liquidity remains strong (~$57M available) with modest net debt (net debt / adjusted EBITDA ~0.56x) and continued capacity on a $75M revolver. Company reiterates full-year pro forma revenue growth expectation of 6–8% and adjusted EBITDA margins in the low-to-mid 20% range (inclusive of IT upgrade costs). Management emphasized disciplined execution, profitable growth and long-term value creation while working through post-ERP stabilization.